June 24th 2025
mRNA technologies offer great promise in immunotherapy and non-immunogenic applications.
February 17th 2025
CHMP Recommends Marketing Authorization for Triple Combination Therapy for Cystic Fibrosis
July 1st 2020EMA’s Committee for Human Medicinal Products (CHMP) has recommended that Kaftrio, a triple combination therapy for the treatment of cystic fibrosis, be authorized for marketing in the European Union.
EMA Recommends a Conditional Marketing Authorization for Kidney Transplant Medicine
July 1st 2020The European Medicines Agency (EMA) has recommended a conditional marketing authorization be granted for Idefirix (imlinfidase) for the treatment of highly sensitized adult patients waiting for a kidney transplant.
Phase III Trial Results Demonstrate Benefit of AstraZeneca’s Breztri Aerosphere
June 25th 2020Full results from the Phase III ETHOS trial have demonstrated a statistically significant reduction in the rate of moderate or severe exacerbations in patients with moderate to very severe COPD after treatment with triple-combination therapy Breztri Aerosphere.
EC Grants Marketing Authorization for Subcutaneous Formulation of Daratumumab
June 5th 2020The European Commission has granted marketing authorization to the Janssen Pharmaceutical Companies of Johnson & Johnson for Darzalex (daratumumab) subcutaneous formulation to treat adults with multiple myeloma.